Marcus had worn the CPAP mask for eleven months before he threw it across the bedroom at 2 a.m. on a Tuesday. Not violently — he wasn’t that kind of person — but deliberately, with the quiet resignation of a man who had simply run out of patience. The hose tangled around his wrist on the way down.
He sat on the edge of the bed, listening to his wife’s steady breathing, thinking about everything he’d been promised: more energy, better focus, lower blood pressure, a longer life. What he’d gotten instead was a red indentation across his nose every single morning, three sinus infections, and a marriage under quiet strain because the machine’s white noise kept her from sleeping deeply.
His sleep physician, to her credit, didn’t lecture him. She slid a small device across her desk — a custom-fitted oral appliance, something between a mouthguard and a retainer — and said, “About forty percent of my CPAP-intolerant patients end up here eventually. Some of them wish they’d started here.”
Marcus’s story isn’t unusual. An estimated 30 to 50 million Americans have obstructive sleep apnea — a condition where the soft tissues of the throat collapse repeatedly during sleep, blocking the airway and triggering micro-arousals that shred sleep architecture without the person ever fully waking. CPAP, continuous positive airway pressure, remains the clinical gold standard. For good reason. It works.
But adherence rates run consistently between 30 and 60 percent at the one-year mark, depending on how you define adherence. A machine gathering dust on a nightstand is treating exactly nobody.
Oral appliance therapy (OAT) entered the mainstream not as a CPAP replacement but as a credible alternative — a genuinely different mechanism, a different evidence base, a different set of trade-offs. What follows is what it is, who it actually works for, and what the evidence reveals once you strip away the marketing on both sides.
The therapy you actually use beats the therapy you abandon. Every time.
What Oral Appliances Actually Do to Your Airway
The physics of obstructive sleep apnea are straightforward, even if the biology underneath isn’t. Fall asleep, and muscle tone throughout the body drops — including in the muscles keeping the pharyngeal airway open. In people with OSA, that relaxation tips over into collapse. Tongue, soft palate, lateral pharyngeal walls fall inward, narrowing or fully occluding the airway.
The brain detects rising carbon dioxide and plummeting oxygen, fires an arousal signal, muscle tone briefly snaps back, the airway reopens. Then the cycle starts again. Sometimes hundreds of times a night.
Mandibular advancement devices (MADs), the most common oral appliance for OSA, interrupt this mechanically. By holding the lower jaw in a protruded position — typically 5 to 10 millimeters forward of its natural resting spot — the device stretches the soft tissues of the pharynx, the genioglossus muscle of the tongue in particular.
That mechanical tension increases the cross-sectional area of the upper airway and makes it less prone to collapse under the reduced muscle tone that comes with sleep.
MRI and endoscopy studies have confirmed exactly what the mechanism predicts. A 2015 study in Sleep, using upper airway MRI during sleep, found MAD therapy increased the retropalatal airway area by an average of 20 percent and the retroglossal area by 18 percent. The palate itself lifted. The lateral walls drew outward.
These aren’t subtle changes. They’re geometrically meaningful increases in the tube a person breathes through all night, every night, for the rest of their life if the condition sits untreated.
The second major category is the tongue-retaining device (TRD), which uses a small suction bulb at the front to hold the tongue forward regardless of jaw position. Less commonly used, but with specific applications for patients with jaw joint issues that rule out mandibular advancement, or those with significant macroglossia — an enlarged tongue serving as the primary anatomical driver of their obstruction.
The evidence base for TRDs is thinner than for MADs, though it’s growing steadily as the technology improves.
Custom-fabricated MADs are made from impressions of the patient’s teeth and adjusted across a series of appointments using calibrated titration screws. The goal is the minimum effective protrusion — enough to open the airway, not so much it strains the temporomandibular joint or causes real muscle soreness.
The titration process typically takes four to twelve weeks, and it’s a substantial part of why outcomes with dental sleep medicine differ so markedly from outcomes with over-the-counter mouthguards, which are neither fitted nor titrated and can’t maintain consistent protrusion once muscles relax during sleep.
Airway anatomy relevant to MAD function extends past the jaw. The hyoid bone — a horseshoe-shaped bone in the throat that a number of muscles attach to — is mechanically connected to the mandible, and advancing the mandible pulls the hyoid forward, which in turn pulls the tongue base forward and enlarges the retroglossal space.
Patients with a more posteriorly positioned hyoid bone — a common anatomical finding in OSA — tend to respond particularly well to mandibular advancement, because the mechanical use is simply more favorable. Lateral cephalometric X-ray analysis including hyoid position has become standard practice in advanced dental sleep medicine evaluation.
The Evidence Base: What the Trials Actually Show
The comparison between CPAP and oral appliance therapy is one of the most studied questions in sleep medicine, and the findings are more nuanced than either camp typically wants to admit. Short version: CPAP reduces the apnea-hypopnea index more thoroughly, but oral appliances produce comparable, and sometimes better, outcomes on the health endpoints that actually matter for patients living with the disease day to day.
The AHI — breathing interruptions per hour of sleep — is the primary metric in most sleep apnea research. A 2015 meta-analysis in JAMA Internal Medicine, 51 randomized trials, found CPAP reduced AHI by roughly 13 events per hour more than oral appliances on average. AHI normalization — getting patients below 5 events per hour — happened in roughly 60 to 70 percent of MAD patients versus 90 percent of CPAP patients.
CPAP is the more complete airway treatment on this specific metric. Nobody should pretend otherwise, and no honest clinician does.
But that same meta-analysis found something that upends the simple hierarchy: on daytime sleepiness (Epworth Sleepiness Scale), blood pressure reduction, quality of life measures, and patient preference, oral appliances performed equivalently to CPAP — and on some measures, better. The explanation for this apparent paradox is straightforward once you actually say it out loud.
CPAP gets used, on average, about four to five hours a night among patients counted as “adherent.” Oral appliances get worn roughly seven hours a night. Moderate treatment applied across the whole sleep period can outperform superior treatment applied to only part of it. The biological effects on blood pressure and daytime function are driven by cumulative hours of airway protection — not by the theoretical maximum efficacy of the device sitting unused on the nightstand.
A landmark 2013 randomized crossover trial by Gagnadoux and colleagues, published in JAMA, directly compared outcomes in 56 patients with moderate-to-severe OSA randomized to three months each of CPAP and MAD therapy. Despite CPAP achieving better AHI reduction, 24-hour ambulatory blood pressure dropped equivalently with both devices. Endothelial function, assessed via flow-mediated dilation of the brachial artery — a validated cardiovascular health marker — also showed no significant difference between the two.
The authors concluded oral appliances were “a legitimate first-line therapy” for mild to moderate OSA and “a viable alternative” even in severe disease for patients who can’t or won’t use CPAP.
The cardiovascular stakes here deserve more emphasis than clinical conversations usually give them. A 2019 prospective cohort study in the Journal of the American College of Cardiology, following 1,023 patients over 10 years, found untreated OSA associated with a 2.3-fold increase in major cardiovascular events — myocardial infarction, stroke, cardiovascular death. Patients who received any effective treatment, CPAP or oral appliance, had event rates comparable to matched controls without OSA at all.
The treatment modality mattered less than whether treatment happened at all, and happened consistently. This has been replicated across multiple large cohort studies and is about as close to settled as observational data gets in sleep medicine.
Cognitive function data has been more mixed, but a 2020 systematic review in Sleep Medicine Reviews, 18 trials, found both CPAP and MAD therapy improved objective cognitive measures — sustained attention, executive function, working memory — compared to sham treatment or no treatment. Effect sizes were similar between devices once use hours were controlled for. Which again points to adherence as the variable that matters, not device superiority.
Who Is a Good Candidate — and Who Isn’t
Oral appliance therapy isn’t for everyone. The honest conversation about candidacy involves several intersecting factors: OSA severity, craniofacial anatomy, dental health, jaw joint status, and — critically — what the patient will actually wear consistently over months and years, not what they’ll wear for the first hopeful week.
Severity guidelines have shifted considerably over the past decade. The American Academy of Sleep Medicine’s 2015 clinical practice guidelines recommend oral appliances as first-line treatment for mild to moderate OSA (AHI 5 to 30) and as an acceptable alternative for severe OSA (AHI above 30) in patients who prefer them or can’t tolerate CPAP.
More permissive than where the field stood a decade earlier, and it reflects accumulating evidence that even in severe cases, many patients with favorable anatomy achieve adequate control with well-fitted, properly titrated appliances. The 2019 update didn’t substantially change this position.
Body mass index is a significant modifying factor. A 2017 meta-regression found treatment response with MADs significantly better in patients with BMI under 30 compared to those above 35. Obesity increases the adipose tissue surrounding the pharynx — deposits in the lateral pharyngeal walls, the tongue base, the parapharyngeal fat pads — and the mechanical advantage of mandibular advancement isn’t always enough to overcome that added burden in heavier patients.
Doesn’t mean patients with elevated BMI can’t benefit. Many do, substantially. But the probability of complete AHI normalization is lower, the possibility of inadequate control is higher, and the conversation about supplementary or alternative interventions should happen proactively — not after several months of watching a suboptimal treatment limp along.
Craniofacial anatomy is arguably the single most predictive factor for response. Patients with retrognathia — a posteriorly positioned lower jaw — tend to respond exceptionally well, because mandibular advancement pulls the jaw toward a more neutral position relative to the upper jaw. The airway benefit is disproportionate to the amount of advancement needed. Patients with a high, narrow palate, significant nasal obstruction, or a short, thick neck tend to see more variable results.
A lateral cephalometric radiograph — an X-ray showing the full side profile of the skull, hair to chin — gives experienced clinicians the anatomical information they use to estimate probability of response and plan the titration strategy.
Dental prerequisites are strict. Enough healthy teeth to anchor the appliance — most designs need at least eight to ten teeth per arch in good periodontal condition. Active periodontal disease (loose teeth, bone loss) is a relative contraindication, because retention forces can accelerate tooth mobility. Active bruxism complicates things further: severe bruxers can crack or deform appliances within months, and grinding forces are substantial enough to accelerate occlusal changes on their own.
Hybrid designs incorporating features of both occlusal splints and mandibular advancement devices have been developed specifically for this population.
Temporomandibular joint health is the most commonly cited contraindication, and the one most subject to clinical judgment rather than a hard rule. Patients with active TMJ disorder — locking, acute inflammatory arthritis, severe pain — are genuinely poor candidates for standard mandibular advancement, because prolonged protrusion can make joint symptoms worse. But “TMJ disorder” covers everything from minor painless clicking to degenerative joint disease, and plenty of patients with mild or historical symptoms use oral appliances successfully with careful titration and close monitoring.
A blanket exclusion based on any TMJ history at all is more conservative than the evidence actually requires.
Custom vs. Over-the-Counter: Why This Distinction Matters Enormously
Custom-fabricated appliances are made from digital or physical impressions of the patient’s specific dentition, ensuring precise fit, retention, and load distribution across the teeth. They adjust in small increments — typically 0.25 to 0.5 millimeter per adjustment — letting the clinician titrate the mandibular advancement to the minimum effective dose for that specific patient’s anatomy. The retention means the device stays put through the whole night.
The titration capability means protrusion can be refined based on objective sleep testing rather than guesswork. These aren’t luxury features. They’re the functional requirements for the therapy to actually work.
Over-the-counter devices are none of this. A 2016 study in Chest directly compared a custom-fitted MAD against a self-fitted thermoplastic device in 100 patients with mild to moderate OSA. The custom device reduced AHI by 51 percent. The OTC device reduced it by 22 percent. On the Epworth Sleepiness Scale, the custom device produced a 3.8-point reduction; the OTC device, 1.2 points.
The researchers also noted OTC devices came with more jaw discomfort, more morning occlusal changes, and more early discontinuation. On every clinically meaningful outcome, the custom device won, and it wasn’t close.
The mechanism behind this gap isn’t mysterious. A poorly fitting device can’t consistently hold the intended degree of protrusion through the night. In the early phase of sleep, when muscle tone is partially preserved, the appliance stays put through mild clenching. As the night wears on and muscle tone drops, a loosely fitting device gradually shifts — losing its therapeutic effect at exactly the moment, REM and deep N3 sleep, when it’s needed most.
Custom devices with tight retention and calibrated protrusion hold their position regardless of muscle tone. Which is the entire reason they work when over-the-counter devices don’t.
Insurance coverage has historically been uneven but has improved substantially over the past decade. Medicare covers oral appliances under durable medical equipment codes E0485 and E0486, and most major commercial insurers provide coverage with appropriate documentation.
The out-of-pocket math differs patient to patient and plan to plan, but the comparison should always be run over a multi-year horizon and should include the full ongoing costs of CPAP — the machine, multiple mask systems, tubing, filters, humidifier components, periodic replacements — which pile up to $400 to $700 a year beyond the initial equipment cost. That number rarely makes it into the sales pitch.
The Side Effect Landscape — Honest, Not Sanitized
Oral appliance therapy has a side effect profile generally milder than CPAP’s, but not trivial, and honest informed consent means discussing it clearly before treatment starts rather than minimizing it to secure patient buy-in. Patients surprised by side effects quit. Patients warned about them tend to tolerate them as an expected feature of the early treatment period rather than a red flag.
Morning jaw soreness affects roughly 70 percent of patients during the first month and typically fades as the masticatory muscles adapt to the mandible’s new resting position. Usually described as a dull ache in the masseter or pterygoid muscles — similar to how muscles feel after unaccustomed exercise. Tends to resolve within 15 to 30 minutes of waking.
Persistent or worsening jaw soreness signals that protrusion advanced too quickly or too far. The correct clinical response: back off titration by one or two increments and give more adaptation time before resuming.
The most clinically significant long-term side effect is occlusal change — shifts in the relationship between upper and lower teeth that can become permanent with prolonged use. A 2014 seven-year longitudinal study by Marklund and colleagues, following patients who’d used MADs for an average of 7.4 years, found 87 percent experienced some degree of bite change.
The most common changes were reduced overbite (vertical overlap of upper over lower teeth) and reduced overjet (horizontal protrusion of the upper teeth). For most patients these changes were minor — one to two millimeters, not clinically symptomatic. For roughly 14 percent, changes were clinically significant and required dental intervention. The risk is real, ongoing, and it accumulates with years of use. Nobody should pretend it doesn’t.
Morning repositioning exercises reduce but don’t eliminate occlusal change risk. The standard protocol: remove the device on waking and immediately run through a series of jaw exercises — closing firmly, moving the jaw laterally, biting into a soft repositioner — designed to stimulate the periodontal ligaments and return the condyles to their natural position before eating or speaking. Published data shows roughly 40 percent reduction in occlusal change with consistent morning repositioning versus device use without the exercises.
TMJ symptoms develop in a minority of patients — 5 to 15 percent, per a 2018 systematic review — and most cases resolve after device adjustment or temporary discontinuation. The causal pathway is almost always the same: excessive protrusion, advanced too fast. Joint symptoms are rarely an inherent incompatibility between mandibular advancement and a given patient’s joint. Almost always, someone just moved too quickly.
Experienced dental sleep medicine providers adjust titration rate based on patient response, checking in weekly by phone or app rather than waiting for the next scheduled appointment to roll around.
The Titration Process: Patience as a Clinical Requirement
One of the most consistent predictors of oral appliance success is how carefully the titration process gets managed — and how patient both the clinician and the patient are willing to be. Rushing titration is the single most reliable path to side effects, premature device abandonment, and mediocre long-term outcomes. This is also where provider quality differences matter most, because titration demands ongoing communication, judgment, and responsiveness that no protocol can fully replace.
Initial protrusion is typically set at 50 to 75 percent of maximum during the first fitting. The device should be comfortable enough to wear a full night from day one — the goal isn’t discomfort tolerance, it’s airway mechanics. Over subsequent weeks, the patient advances the device 0.25 millimeters every three to seven days, guided by symptom reports.
The therapeutic range is highly individual: some patients achieve adequate airway control at 4 millimeters of advancement, others need 9 or 10. Maximum protrusion varies patient to patient, typically 12 to 18 millimeters.
Objective verification of treatment response is essential, and it’s sometimes neglected in practices that prioritize volume over quality — which is a genuine problem in this field, worth naming directly. Symptom improvement — partner-reported snoring reduction, better energy — is real and meaningful but unreliable as the sole endpoint. Patients with severe OSA can feel significantly better on inadequate treatment, because even partial AHI reduction improves sleep architecture enough to produce noticeable functional benefit while real risk lingers underneath.
A patient whose AHI dropped from 45 to 18 may feel dramatically better while still carrying significant cardiovascular risk. A home sleep apnea test, or in-lab polysomnography with the device at its current titration position, is the standard of care for confirming adequate control. Feeling better is not the same as being fixed.
Remote titration protocols have emerged as a real quality-of-life improvement for patients navigating the weeks-long process. A 2020 study in Sleep found remotely guided titration, using a smartphone app tracking snoring acoustics and SpO2, produced outcomes equivalent to in-person titration while requiring far fewer clinic visits.
Not a cost-cutting gimmick. It genuinely allows more frequent, data-guided adjustments that improve the titration trajectory without demanding the patient take time off work for a clinic visit every week.
Once optimal protrusion is established and confirmed by objective sleep testing, the device needs annual re-evaluation with updated sleep testing. OSA severity shifts with weight fluctuation, aging-related changes in muscle tone, hormonal shifts, and nasal anatomy changes from allergies or structural change. An appliance calibrated at 45 years old and 185 pounds may be delivering inadequate control at 58 and 210.
The annual re-evaluation isn’t administrative box-checking. It’s the mechanism that keeps treatment matched to the disease as both keep evolving over years.
Combination Therapy: When One Device Isn’t Enough
MAD combined with positional therapy is the most evidence-supported combination to try first. OSA severity runs substantially worse in the supine position for roughly 60 percent of OSA patients — positional OSA. The mechanism: gravity pulls the tongue and soft palate posteriorly when lying on the back, compounding the airway narrowing the device is already fighting.
A 2021 study in the Journal of Clinical Sleep Medicine found patients with positional OSA who combined a vibrotactile positional device with MAD therapy dropped their residual AHI from 12.4 to 4.1 events per hour — normalization that neither device achieved alone. Modern positional devices, worn as a chest strap or collar, buzz gently when the wearer rolls supine, nudging lateral repositioning without fully waking them.
MAD combined with myofunctional therapy is a more time-intensive but potentially durable combination. Myofunctional therapy involves targeted exercises for the tongue, soft palate, pharyngeal walls, and jaw muscles — essentially physical therapy for the upper airway. A 2015 meta-analysis in Sleep found myofunctional therapy alone reduced AHI by roughly 50 percent in adults and 62 percent in children. The presumed mechanism: increased muscle tone and motor coordination of the pharyngeal muscles, reducing their tendency to collapse in the first place.
Combined with mandibular advancement, the additive effect looks meaningful, though high-quality controlled combination trials remain limited so far.
MAD combined with nasal therapy matters particularly for patients with significant nasal resistance who haven’t been adequately evaluated for it. The upper airway functions as a connected hydraulic system — reduce resistance in the nasal passages and you reduce the total pressure gradient across the whole system, making it easier to maintain pharyngeal patency downstream.
A 2018 study found patients treated for nasal obstruction — corticosteroid spray, saline irrigation, or septoplasty for severe deviation — before MAD titration required significantly less mandibular advancement to hit equivalent AHI reduction, with correspondingly lower side effect burden.
For patients who’ve genuinely failed both CPAP and OAT with appropriate combination strategies tried, hypoglossal nerve stimulation — an implanted device activating the genioglossus muscle in sync with the breathing cycle — is a third-line option with strong evidence in carefully selected patients.
The Inspire device received FDA approval in 2014, and subsequent trials show sustained AHI reduction of greater than 75 percent at five-year follow-up in patients meeting selection criteria: BMI under 35, moderate-to-severe OSA without complete concentric collapse at the palate on drug-induced sleep endoscopy, and absence of central apnea predominance.
The Dental Sleep Medicine Specialty — Navigating Provider Qualifications
Oral appliance therapy sits at the intersection of sleep medicine and dentistry, and navigating that intersection means understanding the credentialing landscape. Not every dentist offering oral appliances has equivalent training in sleep-disordered breathing, and the quality variation across providers is significant enough to matter clinically. Significant enough that it should make people angry, honestly, given what a mismanaged fitting costs a patient in wasted months.
A poorly managed course of OAT — wrong device selection, inadequate titration, no objective outcome verification — can produce side effects without producing benefit, and can leave patients concluding oral appliances “don’t work” when what actually failed was the implementation, not the therapy.
The American Academy of Dental Sleep Medicine (AADSM) offers the Diplomate credential (D.ABDSM), awarded after a rigorous written and oral examination covering sleep medicine, upper airway anatomy, appliance therapy, and side effect management. Diplomates represent the highest level of specialist credentialing in this field. A second credential — Qualified Dentist — is available after approved coursework and a minimum caseload.
Both credentials require ongoing continuing education to maintain, and both are searchable through the AADSM’s online provider directory.
The practical implication: seek a dentist who works collaboratively with a sleep physician, who requires a physician-ordered sleep study before fitting any device, and who performs objective outcome verification with a follow-up sleep test after titration completes. Any provider willing to fit an oral appliance without a prior sleep study — based solely on partner-reported snoring or patient self-report — should be avoided. Full stop.
Snoring without diagnosed OSA is a different condition entirely from diagnosed OSA with an AHI of 35, and the treatment decision for severe disease has to involve a physician who actually understands the cardiovascular stakes at play.
Collaborative care models — where the dental sleep medicine provider and the sleep physician communicate regularly, share sleep study data, and co-manage decisions including when to transition to or add CPAP — consistently produce better outcomes than siloed care. The AADSM has published detailed protocols for this physician-dentist communication, and practices implementing them show lower adverse event rates and better documented treatment responses than practices operating in isolation.
Ask upfront whether the dentist has a referring sleep physician relationship and how they actually communicate about patients. If the answer is vague, that’s the answer.
Long-Term Adherence: What Actually Predicts Whether People Keep Using It
The stated advantage of oral appliance therapy over CPAP is adherence — or more precisely, the probability a given patient actually uses it consistently over years rather than months. But oral appliances aren’t adherence-proof, and overpromising on this dimension sets patients up for a nasty surprise once nightly device use runs into comfort limitations, travel inconvenience, and relationship dynamics that nobody warned them about.
Long-term compliance rates in published prospective studies run 56 to 77 percent at two years, declining gradually in longer follow-up. Better than CPAP adherence. Not dramatically so.
Patient satisfaction in the first month is the single strongest predictor of long-term use. A 2020 study in JAMA Otolaryngology found patients reporting high satisfaction at four weeks had a 78 percent probability of continued device use at two years; patients with low satisfaction at four weeks, 31 percent. The implication is clear: the first month is when clinical investment in follow-up, troubleshooting, and titration adjustment pays its biggest dividend. Skimp there, pay for it later.
A patient who makes it through the first month with manageable symptoms and a real sense of functional benefit is highly likely to continue long-term.
Bed partner satisfaction is a secondary predictor that clinical discussions underrate constantly. Partners who notice meaningful snoring reduction and better sleep in the first weeks become active advocates — they remind the patient, they comment on the improvement, they create social reinforcement measurably associated with adherence. Partners who don’t notice improvement, or who dislike the appliance’s appearance or the change in the patient’s breathing sounds, create the opposite pressure entirely.
Including bed partners in education and follow-up isn’t courtesy. It’s a legitimate behavior change strategy, and clinics that skip it are leaving adherence on the table.
Device characteristics matter more than marketing materials ever admit. Appliances with a smaller vertical opening between the teeth, less total bulk inside the mouth, and some freedom of lateral jaw movement during sleep consistently show better adherence than designs that feel maximally restrictive. The Herbst, Elastic Mandibular Advancement, and Narval CC designs — all permitting limited lateral jaw movement — outperform rigid fixed-advancement designs on comfort and adherence in direct comparisons.
The functional freedom to yawn, to close the mouth more naturally for a second, or to shift position without the jaw locked into a single rigid protrusion correlates with subjective comfort — and ultimately with whether a patient chooses to wear the thing every night for years, not just the first hopeful month.
The Weight Loss Interaction and the GLP-1 Era
But OSA also promotes weight gain through several physiological mechanisms of its own: sleep fragmentation disrupts leptin and ghrelin signaling, driving hyperphagia and a preference for calorie-dense foods; daytime fatigue from fragmented sleep cuts spontaneous physical activity; and the nightly cortisol burden of hypoxic stress promotes visceral adiposity through glucocorticoid-mediated metabolic effects. Effective OSA treatment creates the physiological conditions that make weight management easier. Not automatic. Meaningfully easier, though — which matters.
Patients on oral appliances who achieve significant weight loss — behavioral intervention, bariatric surgery, pharmacological support — should get re-evaluated with objective sleep testing, because their required treatment may have shifted substantially underneath them. Some patients who started MAD therapy at BMI 34 and reach BMI 26 through sustained behavioral change find their OSA has resolved or dropped to mild severity, manageable with positional therapy alone.
Continuing at full therapeutic protrusion in a patient whose disease has substantially remitted isn’t neutral. It keeps carrying side effect risk without proportionate benefit to show for it.
The emergence of GLP-1 receptor agonists as potent weight loss agents has generated real new interest in the OSA-metabolic interaction. The SURMOUNT-OSA trial, published in the New England Journal of Medicine in 2024, found tirzepatide produced a 55 percent reduction in AHI compared to placebo over 52 weeks in patients with OSA and obesity, with 42 percent of participants achieving AHI normalization on medication alone.
This doesn’t make oral appliances obsolete — most trial participants didn’t achieve normalization, the long-term durability of pharmacological OSA treatment is unknown, and plenty of patients aren’t candidates for GLP-1 therapy at all. But it does fundamentally reshape the conversation for patients dealing with significant obesity alongside their OSA. The two questions — how do we treat your airway, how do we treat your metabolic health — are now inextricably linked, whether the specialists involved like coordinating with each other or not.
Insurance, Access, and the Healthcare Navigation Problem
The gap between what the evidence supports and what patients actually receive is nowhere more visible than in oral appliance therapy. A 2022 analysis of Medicare claims data found fewer than 12 percent of Medicare-enrolled OSA patients received any form of oral appliance therapy — despite the evidence supporting its use and Medicare’s own established coverage policy. That gap should bother you more than it probably does.
The path of least clinical resistance — CPAP prescription — dominates because it takes the fewest steps, and because most primary care physicians simply aren’t familiar enough with dental sleep medicine to discuss it as an equivalent option in the first place.
Navigating insurance coverage means knowing a few things. A physician diagnosis of OSA based on a qualifying sleep study is required for coverage under virtually all major plans — a dentist can’t initiate coverage without physician involvement, ever. Most plans require documentation of OSA severity sufficient to meet coverage thresholds, and often prior CPAP trial documentation showing intolerance.
Some plans will cover OAT as first-line therapy without a CPAP trial, if the prescribing physician explicitly documents a medical reason CPAP is inappropriate for that specific patient. The appeals process, when initial claims get denied, has a meaningful success rate — particularly with a letter from the treating sleep physician laying out the clinical rationale.
The access problem runs beyond insurance, too. Dental sleep medicine clusters in urban and suburban areas, with genuine deserts across rural regions. Patients in rural areas often have no Diplomate-credentialed provider within a reasonable drive. Telehealth dental sleep medicine — digital impressions taken by a local general dentist, remotely supervised titration — has partially closed this gap, but managing side effects remotely still requires patient education and a readily available escalation path when something goes wrong.
The field hasn’t fully solved the rural access problem yet, and saying so plainly is part of honest patient communication rather than a footnote to bury.
Oral Appliances Actually: Your Questions Answered
Can I use an oral appliance if I have severe sleep apnea?
Yes, with important caveats. AASM guidelines support oral appliance use in severe OSA (AHI above 30) for patients who prefer it or can’t tolerate CPAP. AHI normalization rates run lower in severe disease than mild-to-moderate cases, and objective follow-up testing to confirm adequate control is mandatory, not optional. Some patients with severe OSA achieve excellent control with well-fitted oral appliances; others don’t, and those patients need to be redirected to CPAP, combination therapy, or surgical evaluation rather than left on a device that isn’t working.
The decision has to involve a sleep physician. Not a dentist operating alone.
Will my insurance cover an oral appliance?
Most major commercial insurers and Medicare cover custom oral appliances for diagnosed OSA, but coverage criteria vary significantly plan to plan. Requirements typically include physician diagnosis from a qualifying sleep study, documentation of OSA severity, and often prior CPAP trial documentation. The dental office providing the appliance typically handles insurance billing; ask for a detailed written breakdown of expected out-of-pocket costs before committing to anything.
Medicare patients should verify the provider is enrolled as a Medicare DME supplier — a different enrollment process than standard Medicare provider status.
How long does the titration process take, and when will I feel better?
Most patients notice subjective improvement in snoring and morning energy within the first two to four weeks, even before reaching optimal protrusion. The full titration process to minimum effective protrusion takes six to twelve weeks of gradual advancement. Objective confirmation with a follow-up sleep study should happen after titration is complete — typically three to four months after the initial fitting.
Side effects like jaw soreness are most prominent in month one and usually fade significantly by weeks six to eight as muscles adapt.
What happens to my bite with long-term oral appliance use?
Bite changes are common and happen in the majority of long-term users. Most changes are minor reductions in overbite and overjet and aren’t symptomatic. Clinically significant changes occur in roughly 14 percent of long-term users based on the best available longitudinal data. Morning repositioning exercises reduce but don’t eliminate this risk.
Bite should be assessed at every annual follow-up, and the provider should photograph occlusion at baseline so any changes get quantified rather than eyeballed and guessed at.
Is there a test to predict whether an oral appliance will work for me before I invest in one?
No single test reliably predicts response, but several approaches improve the odds of matching the right patients to oral appliance therapy. Drug-induced sleep endoscopy (DISE) — sedation used to reproduce sleep-related airway collapse while an endoscope visualizes the site and pattern — gives the most direct anatomical information available. Patients whose collapse is primarily at the tongue base or lateral walls, rather than complete concentric collapse at the palate, respond better to mandibular advancement.
A daytime mandibular advancement test (DMAT), done in-clinic with temporary protrusion to assess snoring reduction, provides a lower-cost directional signal. Predictive models incorporating BMI, jaw anatomy, AHI, and neck circumference have been developed and validated but aren’t yet widely used in routine practice.
The machine that sits on your nightstand unused is treating nobody. The appliance you actually wear every night, even if it doesn’t achieve perfect AHI normalization, is doing real work. The best sleep apnea therapy is the one that happens — consistently, every night, for years.
Marcus’s story ends well. His oral appliance took eight weeks to titrate properly. Follow-up sleep study showed an AHI of 6 — not zero, but well within the treated range. His wife mentioned within the first week that she could no longer hear him breathing from her side of the bed. He doesn’t think about the appliance much anymore. He puts it in, falls asleep, wakes up feeling like an actual person again.
The best medical devices are the ones you forget you’re wearing.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map